A Randomized, Multicenter, Double-blind, Placebo-controlled, Cross-over Study of the Efficacy and Safety of BMS-954561 in Patients With Post-herpetic Neuralgia (PHN).
Latest Information Update: 09 Dec 2015
At a glance
- Drugs BMS 954561 (Primary)
- Indications Postherpetic neuralgia
- Focus Therapeutic Use
- 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Mar 2012 Planned end date changed from 1 Mar 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 13 Jan 2012 Planned end date changed from 1 Jul 2012 to 1 Mar 2012 as reported by ClinicalTrials.gov.